Javascript must be enabled for the correct page display

The TRAIL-receptors 1 (DR4) and 2 (DR5) contribute differently to TRAIL-mediated apoptosis

Bronsema, J.H. (2013) The TRAIL-receptors 1 (DR4) and 2 (DR5) contribute differently to TRAIL-mediated apoptosis. Bachelor's Thesis, Biology.

LST_Bc_2013_JHBronsema.pdf - Published Version

Download (622kB) | Preview
[img] Text
AkkoordKruyt.pdf - Other
Restricted to Repository staff only

Download (31kB)


Cancer is a major disease which had 12.7 million cases worldwide in 2008 of which 82.000 were in The Netherlands. Because of this high incidence it is important to develop new therapies. The TNF-related apoptosis inducing ligand (TRAIL) is a promising new drug that induces cell death or apoptosis in tumor cells. Important advantages of TRAIL are that is does not affect healthy cells and that it can be used in many different cell types making it a wide-range drug. TRAIL can induce apoptosis through two receptors: TRAIL-R1 (DR4) and TRAIL-R2 (DR5). In this review we analysed whether TRAIL-R1 and TRAIL-R2 contribute differently to TRAIL-mediated apoptosis and what the underlying mechanisms are. This review showed that there are different contributions of TRAIL-R1 and TRAIL-R2 to TRAIL-mediated apoptosis which might be cell type specific.TRAIL-R1 induced apoptosis predominantly in leukemic cancer cells, melanoma cancer cells and pancreatic cancer cells, whereas TRAIL-R2 induced apoptosis predominantly in colon cancer cells, breast cancer cells and glioblastoma cancer cells. The underlying mechanisms are not well understood and it is important that they are identified. That way it might be possible to determine whether a tumor is a TRAIL-R1 type or a TRAIL-R2 type. Treatment with specific TRAIL receptor variants will be useful, because it maximizes the success of the therapy due to the higher affinity.

Item Type: Thesis (Bachelor's Thesis)
Degree programme: Biology
Thesis type: Bachelor's Thesis
Language: English
Date Deposited: 15 Feb 2018 07:53
Last Modified: 15 Feb 2018 07:53

Actions (login required)

View Item View Item